Elective upper-neck versus whole-neck irradiation of the uninvolved neck in patients with nasopharyngeal carcinoma: an open-label, non-inferiority, multicentre, randomised phase 3 trial
The aim of this trial was to address whether elective ipsilateral upper-neck irradiation (UNI) sparing the uninvolved lower neck provides similar regional relapse-free survival compared with standard whole-neck irradiation (WNI) in patients with nasopharyngeal carcinoma. This open-label, non-inferio...
Saved in:
Published in | The lancet oncology Vol. 23; no. 4; pp. 479 - 490 |
---|---|
Main Authors | , , , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
England
Elsevier Ltd
01.04.2022
Elsevier Limited |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | The aim of this trial was to address whether elective ipsilateral upper-neck irradiation (UNI) sparing the uninvolved lower neck provides similar regional relapse-free survival compared with standard whole-neck irradiation (WNI) in patients with nasopharyngeal carcinoma.
This open-label, non-inferiority, randomised, controlled, phase 3 trial was done at three Chinese medical centres. Patients aged 18–65 years with untreated, non-keratinising, non-distant metastatic (M0) nasopharyngeal carcinoma; with N0–N1 disease (according to International Union Against Cancer–American Joint Committee on Cancer TNM classification, seventh edition); and a Karnofsky performance status score of 70 or higher were randomly assigned (1:1) to receive elective UNI or WNI of the uninvolved neck. Total radiation doses of 70 Gy (for the primary tumour volume and the enlarged retropharyngeal nodes), 66–70 Gy (for the involved cervical lymph nodes), 60–62 Gy (for the high-risk target volume), and 54–56 Gy (for the low-risk target volume) were administered in 30–33 fractions, five fractions per week. Patients with stage II–IVA disease were recommended to receive combined intravenous cisplatin-based chemotherapy (either induction chemotherapy followed by concurrent chemoradiotherapy or concurrent chemoradiotherapy alone). Randomisation was done centrally by the Clinical Trials Centre of Sun Yat-sen University Cancer Centre by means of a computer-generated random number code with a block size of four. Patients were stratified according to treatment centre and nodal status. Investigators and patients were not masked to treatment allocation. The primary endpoint was regional relapse-free survival in the intention-to-treat population. Non-inferiority was indicated if the upper limit of the 95% CI of the difference in 3-year regional relapse-free survival between the UNI and WNI groups was within 8%. Adverse events were analysed in the safety population (defined as all patients who commenced the randomly assigned treatment). This study is registered with ClinicalTrials.gov, NCT02642107, and is closed.
Between Jan 22, 2016, and May 23, 2018, 446 patients from 469 screened were randomly assigned to receive UNI (n=224) or WNI (n=222). Median follow-up was 53 months (IQR 46–59). 3-year regional relapse-free survival was similar in the UNI and WNI groups (97·7% [95% CI 95·7–99·7] in the UNI group vs 96·3% [93·8–98·8] in the WNI group; difference −1·4% [95% CI −4·6 to 1·8]; pnon-inferiority<0·0001). Although acute radiation-related toxic effects were similar between the groups, the incidence of late toxicity was lower in the UNI group than in the WNI group, including any-grade hypothyroidism (66 [30%] of 222 patients vs 87 [39%] of 221), skin toxicity (32 [14%] vs 55 [25%]), dysphagia (38 [17%] vs 71 [32%]), and neck tissue damage (50 [23%] vs 88 [40%]). No patients died during treatment. After treatment, one patient in the WNI group died from a non-cancer-related cause (dermatomyositis).
Elective UNI of the uninvolved neck provides similar regional control and results in less radiation toxicity compared with standard WNI in patients with N0–N1 nasopharyngeal carcinoma.
Sun Yat-sen University Clinical Research 5010 Program, the Natural Science Foundation of Guangdong Province, and the Overseas Expertise Introduction Project for Discipline Innovation.
For the Chinese translation of the abstract see Supplementary Materials section. |
---|---|
AbstractList | The aim of this trial was to address whether elective ipsilateral upper-neck irradiation (UNI) sparing the uninvolved lower neck provides similar regional relapse-free survival compared with standard whole-neck irradiation (WNI) in patients with nasopharyngeal carcinoma.BACKGROUNDThe aim of this trial was to address whether elective ipsilateral upper-neck irradiation (UNI) sparing the uninvolved lower neck provides similar regional relapse-free survival compared with standard whole-neck irradiation (WNI) in patients with nasopharyngeal carcinoma.This open-label, non-inferiority, randomised, controlled, phase 3 trial was done at three Chinese medical centres. Patients aged 18-65 years with untreated, non-keratinising, non-distant metastatic (M0) nasopharyngeal carcinoma; with N0-N1 disease (according to International Union Against Cancer-American Joint Committee on Cancer TNM classification, seventh edition); and a Karnofsky performance status score of 70 or higher were randomly assigned (1:1) to receive elective UNI or WNI of the uninvolved neck. Total radiation doses of 70 Gy (for the primary tumour volume and the enlarged retropharyngeal nodes), 66-70 Gy (for the involved cervical lymph nodes), 60-62 Gy (for the high-risk target volume), and 54-56 Gy (for the low-risk target volume) were administered in 30-33 fractions, five fractions per week. Patients with stage II-IVA disease were recommended to receive combined intravenous cisplatin-based chemotherapy (either induction chemotherapy followed by concurrent chemoradiotherapy or concurrent chemoradiotherapy alone). Randomisation was done centrally by the Clinical Trials Centre of Sun Yat-sen University Cancer Centre by means of a computer-generated random number code with a block size of four. Patients were stratified according to treatment centre and nodal status. Investigators and patients were not masked to treatment allocation. The primary endpoint was regional relapse-free survival in the intention-to-treat population. Non-inferiority was indicated if the upper limit of the 95% CI of the difference in 3-year regional relapse-free survival between the UNI and WNI groups was within 8%. Adverse events were analysed in the safety population (defined as all patients who commenced the randomly assigned treatment). This study is registered with ClinicalTrials.gov, NCT02642107, and is closed.METHODSThis open-label, non-inferiority, randomised, controlled, phase 3 trial was done at three Chinese medical centres. Patients aged 18-65 years with untreated, non-keratinising, non-distant metastatic (M0) nasopharyngeal carcinoma; with N0-N1 disease (according to International Union Against Cancer-American Joint Committee on Cancer TNM classification, seventh edition); and a Karnofsky performance status score of 70 or higher were randomly assigned (1:1) to receive elective UNI or WNI of the uninvolved neck. Total radiation doses of 70 Gy (for the primary tumour volume and the enlarged retropharyngeal nodes), 66-70 Gy (for the involved cervical lymph nodes), 60-62 Gy (for the high-risk target volume), and 54-56 Gy (for the low-risk target volume) were administered in 30-33 fractions, five fractions per week. Patients with stage II-IVA disease were recommended to receive combined intravenous cisplatin-based chemotherapy (either induction chemotherapy followed by concurrent chemoradiotherapy or concurrent chemoradiotherapy alone). Randomisation was done centrally by the Clinical Trials Centre of Sun Yat-sen University Cancer Centre by means of a computer-generated random number code with a block size of four. Patients were stratified according to treatment centre and nodal status. Investigators and patients were not masked to treatment allocation. The primary endpoint was regional relapse-free survival in the intention-to-treat population. Non-inferiority was indicated if the upper limit of the 95% CI of the difference in 3-year regional relapse-free survival between the UNI and WNI groups was within 8%. Adverse events were analysed in the safety population (defined as all patients who commenced the randomly assigned treatment). This study is registered with ClinicalTrials.gov, NCT02642107, and is closed.Between Jan 22, 2016, and May 23, 2018, 446 patients from 469 screened were randomly assigned to receive UNI (n=224) or WNI (n=222). Median follow-up was 53 months (IQR 46-59). 3-year regional relapse-free survival was similar in the UNI and WNI groups (97·7% [95% CI 95·7-99·7] in the UNI group vs 96·3% [93·8-98·8] in the WNI group; difference -1·4% [95% CI -4·6 to 1·8]; pnon-inferiority<0·0001). Although acute radiation-related toxic effects were similar between the groups, the incidence of late toxicity was lower in the UNI group than in the WNI group, including any-grade hypothyroidism (66 [30%] of 222 patients vs 87 [39%] of 221), skin toxicity (32 [14%] vs 55 [25%]), dysphagia (38 [17%] vs 71 [32%]), and neck tissue damage (50 [23%] vs 88 [40%]). No patients died during treatment. After treatment, one patient in the WNI group died from a non-cancer-related cause (dermatomyositis).FINDINGSBetween Jan 22, 2016, and May 23, 2018, 446 patients from 469 screened were randomly assigned to receive UNI (n=224) or WNI (n=222). Median follow-up was 53 months (IQR 46-59). 3-year regional relapse-free survival was similar in the UNI and WNI groups (97·7% [95% CI 95·7-99·7] in the UNI group vs 96·3% [93·8-98·8] in the WNI group; difference -1·4% [95% CI -4·6 to 1·8]; pnon-inferiority<0·0001). Although acute radiation-related toxic effects were similar between the groups, the incidence of late toxicity was lower in the UNI group than in the WNI group, including any-grade hypothyroidism (66 [30%] of 222 patients vs 87 [39%] of 221), skin toxicity (32 [14%] vs 55 [25%]), dysphagia (38 [17%] vs 71 [32%]), and neck tissue damage (50 [23%] vs 88 [40%]). No patients died during treatment. After treatment, one patient in the WNI group died from a non-cancer-related cause (dermatomyositis).Elective UNI of the uninvolved neck provides similar regional control and results in less radiation toxicity compared with standard WNI in patients with N0-N1 nasopharyngeal carcinoma.INTERPRETATIONElective UNI of the uninvolved neck provides similar regional control and results in less radiation toxicity compared with standard WNI in patients with N0-N1 nasopharyngeal carcinoma.Sun Yat-sen University Clinical Research 5010 Program, the Natural Science Foundation of Guangdong Province, and the Overseas Expertise Introduction Project for Discipline Innovation.FUNDINGSun Yat-sen University Clinical Research 5010 Program, the Natural Science Foundation of Guangdong Province, and the Overseas Expertise Introduction Project for Discipline Innovation.For the Chinese translation of the abstract see Supplementary Materials section.TRANSLATIONFor the Chinese translation of the abstract see Supplementary Materials section. The aim of this trial was to address whether elective ipsilateral upper-neck irradiation (UNI) sparing the uninvolved lower neck provides similar regional relapse-free survival compared with standard whole-neck irradiation (WNI) in patients with nasopharyngeal carcinoma. This open-label, non-inferiority, randomised, controlled, phase 3 trial was done at three Chinese medical centres. Patients aged 18–65 years with untreated, non-keratinising, non-distant metastatic (M0) nasopharyngeal carcinoma; with N0–N1 disease (according to International Union Against Cancer–American Joint Committee on Cancer TNM classification, seventh edition); and a Karnofsky performance status score of 70 or higher were randomly assigned (1:1) to receive elective UNI or WNI of the uninvolved neck. Total radiation doses of 70 Gy (for the primary tumour volume and the enlarged retropharyngeal nodes), 66–70 Gy (for the involved cervical lymph nodes), 60–62 Gy (for the high-risk target volume), and 54–56 Gy (for the low-risk target volume) were administered in 30–33 fractions, five fractions per week. Patients with stage II–IVA disease were recommended to receive combined intravenous cisplatin-based chemotherapy (either induction chemotherapy followed by concurrent chemoradiotherapy or concurrent chemoradiotherapy alone). Randomisation was done centrally by the Clinical Trials Centre of Sun Yat-sen University Cancer Centre by means of a computer-generated random number code with a block size of four. Patients were stratified according to treatment centre and nodal status. Investigators and patients were not masked to treatment allocation. The primary endpoint was regional relapse-free survival in the intention-to-treat population. Non-inferiority was indicated if the upper limit of the 95% CI of the difference in 3-year regional relapse-free survival between the UNI and WNI groups was within 8%. Adverse events were analysed in the safety population (defined as all patients who commenced the randomly assigned treatment). This study is registered with ClinicalTrials.gov, NCT02642107, and is closed. Between Jan 22, 2016, and May 23, 2018, 446 patients from 469 screened were randomly assigned to receive UNI (n=224) or WNI (n=222). Median follow-up was 53 months (IQR 46–59). 3-year regional relapse-free survival was similar in the UNI and WNI groups (97·7% [95% CI 95·7–99·7] in the UNI group vs 96·3% [93·8–98·8] in the WNI group; difference −1·4% [95% CI −4·6 to 1·8]; pnon-inferiority<0·0001). Although acute radiation-related toxic effects were similar between the groups, the incidence of late toxicity was lower in the UNI group than in the WNI group, including any-grade hypothyroidism (66 [30%] of 222 patients vs 87 [39%] of 221), skin toxicity (32 [14%] vs 55 [25%]), dysphagia (38 [17%] vs 71 [32%]), and neck tissue damage (50 [23%] vs 88 [40%]). No patients died during treatment. After treatment, one patient in the WNI group died from a non-cancer-related cause (dermatomyositis). Elective UNI of the uninvolved neck provides similar regional control and results in less radiation toxicity compared with standard WNI in patients with N0–N1 nasopharyngeal carcinoma. Sun Yat-sen University Clinical Research 5010 Program, the Natural Science Foundation of Guangdong Province, and the Overseas Expertise Introduction Project for Discipline Innovation. For the Chinese translation of the abstract see Supplementary Materials section. SummaryBackgroundThe aim of this trial was to address whether elective ipsilateral upper-neck irradiation (UNI) sparing the uninvolved lower neck provides similar regional relapse-free survival compared with standard whole-neck irradiation (WNI) in patients with nasopharyngeal carcinoma. MethodsThis open-label, non-inferiority, randomised, controlled, phase 3 trial was done at three Chinese medical centres. Patients aged 18–65 years with untreated, non-keratinising, non-distant metastatic (M0) nasopharyngeal carcinoma; with N0–N1 disease (according to International Union Against Cancer–American Joint Committee on Cancer TNM classification, seventh edition); and a Karnofsky performance status score of 70 or higher were randomly assigned (1:1) to receive elective UNI or WNI of the uninvolved neck. Total radiation doses of 70 Gy (for the primary tumour volume and the enlarged retropharyngeal nodes), 66–70 Gy (for the involved cervical lymph nodes), 60–62 Gy (for the high-risk target volume), and 54–56 Gy (for the low-risk target volume) were administered in 30–33 fractions, five fractions per week. Patients with stage II–IVA disease were recommended to receive combined intravenous cisplatin-based chemotherapy (either induction chemotherapy followed by concurrent chemoradiotherapy or concurrent chemoradiotherapy alone). Randomisation was done centrally by the Clinical Trials Centre of Sun Yat-sen University Cancer Centre by means of a computer-generated random number code with a block size of four. Patients were stratified according to treatment centre and nodal status. Investigators and patients were not masked to treatment allocation. The primary endpoint was regional relapse-free survival in the intention-to-treat population. Non-inferiority was indicated if the upper limit of the 95% CI of the difference in 3-year regional relapse-free survival between the UNI and WNI groups was within 8%. Adverse events were analysed in the safety population (defined as all patients who commenced the randomly assigned treatment). This study is registered with ClinicalTrials.gov, NCT02642107, and is closed. FindingsBetween Jan 22, 2016, and May 23, 2018, 446 patients from 469 screened were randomly assigned to receive UNI (n=224) or WNI (n=222). Median follow-up was 53 months (IQR 46–59). 3-year regional relapse-free survival was similar in the UNI and WNI groups (97·7% [95% CI 95·7–99·7] in the UNI group vs 96·3% [93·8–98·8] in the WNI group; difference −1·4% [95% CI −4·6 to 1·8]; p non-inferiority<0·0001). Although acute radiation-related toxic effects were similar between the groups, the incidence of late toxicity was lower in the UNI group than in the WNI group, including any-grade hypothyroidism (66 [30%] of 222 patients vs 87 [39%] of 221), skin toxicity (32 [14%] vs 55 [25%]), dysphagia (38 [17%] vs 71 [32%]), and neck tissue damage (50 [23%] vs 88 [40%]). No patients died during treatment. After treatment, one patient in the WNI group died from a non-cancer-related cause (dermatomyositis). InterpretationElective UNI of the uninvolved neck provides similar regional control and results in less radiation toxicity compared with standard WNI in patients with N0–N1 nasopharyngeal carcinoma. FundingSun Yat-sen University Clinical Research 5010 Program, the Natural Science Foundation of Guangdong Province, and the Overseas Expertise Introduction Project for Discipline Innovation. TranslationFor the Chinese translation of the abstract see Supplementary Materials section. The aim of this trial was to address whether elective ipsilateral upper-neck irradiation (UNI) sparing the uninvolved lower neck provides similar regional relapse-free survival compared with standard whole-neck irradiation (WNI) in patients with nasopharyngeal carcinoma. This open-label, non-inferiority, randomised, controlled, phase 3 trial was done at three Chinese medical centres. Patients aged 18-65 years with untreated, non-keratinising, non-distant metastatic (M0) nasopharyngeal carcinoma; with N0-N1 disease (according to International Union Against Cancer-American Joint Committee on Cancer TNM classification, seventh edition); and a Karnofsky performance status score of 70 or higher were randomly assigned (1:1) to receive elective UNI or WNI of the uninvolved neck. Total radiation doses of 70 Gy (for the primary tumour volume and the enlarged retropharyngeal nodes), 66-70 Gy (for the involved cervical lymph nodes), 60-62 Gy (for the high-risk target volume), and 54-56 Gy (for the low-risk target volume) were administered in 30-33 fractions, five fractions per week. Patients with stage II-IVA disease were recommended to receive combined intravenous cisplatin-based chemotherapy (either induction chemotherapy followed by concurrent chemoradiotherapy or concurrent chemoradiotherapy alone). Randomisation was done centrally by the Clinical Trials Centre of Sun Yat-sen University Cancer Centre by means of a computer-generated random number code with a block size of four. Patients were stratified according to treatment centre and nodal status. Investigators and patients were not masked to treatment allocation. The primary endpoint was regional relapse-free survival in the intention-to-treat population. Non-inferiority was indicated if the upper limit of the 95% CI of the difference in 3-year regional relapse-free survival between the UNI and WNI groups was within 8%. Adverse events were analysed in the safety population (defined as all patients who commenced the randomly assigned treatment). This study is registered with ClinicalTrials.gov, NCT02642107, and is closed. Between Jan 22, 2016, and May 23, 2018, 446 patients from 469 screened were randomly assigned to receive UNI (n=224) or WNI (n=222). Median follow-up was 53 months (IQR 46-59). 3-year regional relapse-free survival was similar in the UNI and WNI groups (97·7% [95% CI 95·7-99·7] in the UNI group vs 96·3% [93·8-98·8] in the WNI group; difference -1·4% [95% CI -4·6 to 1·8]; p <0·0001). Although acute radiation-related toxic effects were similar between the groups, the incidence of late toxicity was lower in the UNI group than in the WNI group, including any-grade hypothyroidism (66 [30%] of 222 patients vs 87 [39%] of 221), skin toxicity (32 [14%] vs 55 [25%]), dysphagia (38 [17%] vs 71 [32%]), and neck tissue damage (50 [23%] vs 88 [40%]). No patients died during treatment. After treatment, one patient in the WNI group died from a non-cancer-related cause (dermatomyositis). Elective UNI of the uninvolved neck provides similar regional control and results in less radiation toxicity compared with standard WNI in patients with N0-N1 nasopharyngeal carcinoma. Sun Yat-sen University Clinical Research 5010 Program, the Natural Science Foundation of Guangdong Province, and the Overseas Expertise Introduction Project for Discipline Innovation. For the Chinese translation of the abstract see Supplementary Materials section. Summary Background The aim of this trial was to address whether elective ipsilateral upper-neck irradiation (UNI) sparing the uninvolved lower neck provides similar regional relapse-free survival compared with standard whole-neck irradiation (WNI) in patients with nasopharyngeal carcinoma. Methods This open-label, non-inferiority, randomised, controlled, phase 3 trial was done at three Chinese medical centres. Patients aged 18–65 years with untreated, non-keratinising, non-distant metastatic (M0) nasopharyngeal carcinoma; with N0–N1 disease (according to International Union Against Cancer–American Joint Committee on Cancer TNM classification, seventh edition); and a Karnofsky performance status score of 70 or higher were randomly assigned (1:1) to receive elective UNI or WNI of the uninvolved neck. Total radiation doses of 70 Gy (for the primary tumour volume and the enlarged retropharyngeal nodes), 66–70 Gy (for the involved cervical lymph nodes), 60–62 Gy (for the high-risk target volume), and 54–56 Gy (for the low-risk target volume) were administered in 30–33 fractions, five fractions per week. Patients with stage II–IVA disease were recommended to receive combined intravenous cisplatin-based chemotherapy (either induction chemotherapy followed by concurrent chemoradiotherapy or concurrent chemoradiotherapy alone). Randomisation was done centrally by the Clinical Trials Centre of Sun Yat-sen University Cancer Centre by means of a computer-generated random number code with a block size of four. Patients were stratified according to treatment centre and nodal status. Investigators and patients were not masked to treatment allocation. The primary endpoint was regional relapse-free survival in the intention-to-treat population. Non-inferiority was indicated if the upper limit of the 95% CI of the difference in 3-year regional relapse-free survival between the UNI and WNI groups was within 8%. Adverse events were analysed in the safety population (defined as all patients who commenced the randomly assigned treatment). This study is registered with ClinicalTrials.gov, NCT02642107, and is closed. Findings Between Jan 22, 2016, and May 23, 2018, 446 patients from 469 screened were randomly assigned to receive UNI (n=224) or WNI (n=222). Median follow-up was 53 months (IQR 46–59). 3-year regional relapse-free survival was similar in the UNI and WNI groups (97·7% [95% CI 95·7–99·7] in the UNI group vs 96·3% [93·8–98·8] in the WNI group; difference −1·4% [95% CI −4·6 to 1·8]; pnon-inferiority<0·0001). Although acute radiation-related toxic effects were similar between the groups, the incidence of late toxicity was lower in the UNI group than in the WNI group, including any-grade hypothyroidism (66 [30%] of 222 patients vs 87 [39%] of 221), skin toxicity (32 [14%] vs 55 [25%]), dysphagia (38 [17%] vs 71 [32%]), and neck tissue damage (50 [23%] vs 88 [40%]). No patients died during treatment. After treatment, one patient in the WNI group died from a non-cancer-related cause (dermatomyositis). Interpretation Elective UNI of the uninvolved neck provides similar regional control and results in less radiation toxicity compared with standard WNI in patients with N0–N1 nasopharyngeal carcinoma. Funding Sun Yat-sen University Clinical Research 5010 Program, the Natural Science Foundation of Guangdong Province, and the Overseas Expertise Introduction Project for Discipline Innovation. Translation For the Chinese translation of the abstract see Supplementary Materials section. |
Author | Sun, Ying Mao, Yan-Ping Hu, Wei-Han Zhou, Guan-Qun Qin, Guan-Jie Jiang, Wei Wu, Yi-Shan Chen, Lei Liang, Shao-Qiang Xie, Fang-Yun Huang, Cheng-Long Li, Ji-Bin Liu, Qing Huang, Shao Hui Ma, Jun Tang, Ling-Long Zhang, Ning |
Author_xml | – sequence: 1 givenname: Ling-Long surname: Tang fullname: Tang, Ling-Long organization: Department of Radiation Oncology, Sun Yat-sen University Cancer Center, the State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangzhou, China – sequence: 2 givenname: Cheng-Long surname: Huang fullname: Huang, Cheng-Long organization: Department of Radiation Oncology, Sun Yat-sen University Cancer Center, the State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangzhou, China – sequence: 3 givenname: Ning surname: Zhang fullname: Zhang, Ning organization: Department of Radiation Oncology, First People's Hospital of Foshan, Foshan, China – sequence: 4 givenname: Wei surname: Jiang fullname: Jiang, Wei organization: Department of Radiation Oncology, Affiliated Hospital of Guilin Medical University, Guilin, China – sequence: 5 givenname: Yi-Shan surname: Wu fullname: Wu, Yi-Shan organization: Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, the State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangzhou, China – sequence: 6 givenname: Shao Hui surname: Huang fullname: Huang, Shao Hui organization: Department of Radiation Oncology, The Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada – sequence: 7 givenname: Yan-Ping surname: Mao fullname: Mao, Yan-Ping organization: Department of Radiation Oncology, Sun Yat-sen University Cancer Center, the State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangzhou, China – sequence: 8 givenname: Qing surname: Liu fullname: Liu, Qing organization: Clinical Trials Centre, Sun Yat-sen University Cancer Center, the State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangzhou, China – sequence: 9 givenname: Ji-Bin surname: Li fullname: Li, Ji-Bin organization: Clinical Trials Centre, Sun Yat-sen University Cancer Center, the State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangzhou, China – sequence: 10 givenname: Shao-Qiang surname: Liang fullname: Liang, Shao-Qiang organization: Department of Radiation Oncology, First People's Hospital of Foshan, Foshan, China – sequence: 11 givenname: Guan-Jie surname: Qin fullname: Qin, Guan-Jie organization: Department of Radiation Oncology, Affiliated Hospital of Guilin Medical University, Guilin, China – sequence: 12 givenname: Wei-Han surname: Hu fullname: Hu, Wei-Han organization: Department of Radiation Oncology, Sun Yat-sen University Cancer Center, the State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangzhou, China – sequence: 13 givenname: Ying surname: Sun fullname: Sun, Ying organization: Department of Radiation Oncology, Sun Yat-sen University Cancer Center, the State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangzhou, China – sequence: 14 givenname: Fang-Yun surname: Xie fullname: Xie, Fang-Yun organization: Department of Radiation Oncology, Sun Yat-sen University Cancer Center, the State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangzhou, China – sequence: 15 givenname: Lei surname: Chen fullname: Chen, Lei organization: Department of Radiation Oncology, Sun Yat-sen University Cancer Center, the State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangzhou, China – sequence: 16 givenname: Guan-Qun surname: Zhou fullname: Zhou, Guan-Qun organization: Department of Radiation Oncology, Sun Yat-sen University Cancer Center, the State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangzhou, China – sequence: 17 givenname: Jun surname: Ma fullname: Ma, Jun email: majun2@mail.sysu.edu.cn organization: Department of Radiation Oncology, Sun Yat-sen University Cancer Center, the State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangzhou, China |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/35240053$$D View this record in MEDLINE/PubMed |
BookMark | eNqNkstu1DAUhiNURC_wCCBLbIo0AV8n0yJAqCoXqRILYG05zgnj1mMH2xk0j8bbcWZSuhgJlVUi6_u_HJ8_x9VBiAGq6imjLxll81dfmWxozalUp5y_oJSqRS0fVEd4LGslF4uD3fuEHFbHOV9TyhpG1aPqUCguMSGOqt-XHmxxayDjMECqA9gbsoaUx0x-LaOH6cSlZDpniouBxJ6UJfLBhXX0a-jIhAQyIAChYNKVJQkmx2Fp0ib8AOOJNcm6EFfmnBiUDBBqb1rwM4I3q13oIbmYXNnMyGr0xVk0JZiRZEIXVy7jd9CWgQhSkjP-cfWwNz7Dk9vnSfX9w-W3i0_11ZePny_eX9VWUV7qhbGcNVII2VqmeN9zzhaiAaoUFwJkK89EcybmtOtZ03aibztjO8WhFVZ1Cy5OqtPJO6T4c4RcNA5jwXsTII5Z87mYM8kUpYg-30Ov45gCToeUxBkahJB6dkuN7Qo6PSS3wi3pv6UgoCbApphzgv4OYVRvy9e78vW2Wc253pWvJeZe7-WsK7vOSjLO35t-N6UBl7l2kHS22KaFziX8RXQX3b2Gt3sG611w1vgb2EC-2wXTGUOTZOvgfGfYCt78W_AfA_wBDCTyrA |
CitedBy_id | crossref_primary_10_1016_S1470_2045_22_00262_5 crossref_primary_10_1016_j_radonc_2022_10_034 crossref_primary_10_1002_pro6_1219 crossref_primary_10_1007_s44178_023_00045_w crossref_primary_10_1016_j_radonc_2023_109595 crossref_primary_10_1007_s00066_022_01986_3 crossref_primary_10_1186_s12885_024_12391_7 crossref_primary_10_1001_jamanetworkopen_2022_55209 crossref_primary_10_1016_j_radonc_2024_110225 crossref_primary_10_3389_fmed_2022_996127 crossref_primary_10_1007_s00761_024_01657_1 crossref_primary_10_1016_j_media_2024_103103 crossref_primary_10_1038_s41597_024_03890_0 crossref_primary_10_1186_s12885_025_13865_y crossref_primary_10_1200_JCO_23_02086 crossref_primary_10_1016_j_semradonc_2025_01_001 crossref_primary_10_1245_s10434_024_16145_4 crossref_primary_10_3390_cancers16020383 crossref_primary_10_1016_j_semradonc_2025_01_003 crossref_primary_10_1186_s13643_022_02123_y crossref_primary_10_3390_cancers15030672 crossref_primary_10_1016_j_radonc_2025_110713 crossref_primary_10_1016_j_radonc_2022_11_005 crossref_primary_10_1186_s12885_023_11212_7 crossref_primary_10_1177_03008916231154765 crossref_primary_10_1016_j_crad_2024_01_017 crossref_primary_10_1016_j_radonc_2023_110032 crossref_primary_10_1016_S1470_2045_22_00263_7 crossref_primary_10_1016_j_ijrobp_2023_02_047 crossref_primary_10_1002_cam4_6723 crossref_primary_10_1016_S1470_2045_22_00096_1 crossref_primary_10_3390_cancers14235773 crossref_primary_10_1097_MOO_0000000000000942 crossref_primary_10_1016_S1470_2045_22_00282_0 crossref_primary_10_1016_j_radonc_2024_110086 crossref_primary_10_1016_j_xcrm_2024_101594 crossref_primary_10_1016_j_eswa_2024_125208 crossref_primary_10_1002_pro6_70007 crossref_primary_10_1360_SSV_2024_0275 crossref_primary_10_3390_cancers16112085 crossref_primary_10_1016_j_critrevonc_2023_103994 crossref_primary_10_1016_j_radonc_2022_109447 crossref_primary_10_1016_j_radonc_2023_109860 crossref_primary_10_1038_s41415_022_5195_5 crossref_primary_10_1007_s44178_023_00046_9 crossref_primary_10_3390_jcm11123297 crossref_primary_10_1016_j_oraloncology_2022_106022 crossref_primary_10_1016_j_ijrobp_2022_12_041 crossref_primary_10_1158_1078_0432_CCR_23_3274 crossref_primary_10_1016_j_prro_2022_04_005 crossref_primary_10_1111_ajco_13955 crossref_primary_10_1136_bmj_2022_072133 crossref_primary_10_20960_revcancer_00070 |
Cites_doi | 10.1016/S1470-2045(18)30104-9 10.5732/cjc.012.10095 10.1016/j.jclinepi.2010.11.016 10.1016/S0140-6736(18)32752-1 10.1016/S0140-6736(19)30956-0 10.1016/S1470-2045(21)00075-9 10.1245/s10434-011-2018-3 10.3322/caac.21492 10.1016/j.ijrobp.2010.03.024 10.1002/cncr.24049 10.1136/bmjopen-2020-044480 10.1016/j.radonc.2020.03.012 10.1016/j.radonc.2012.12.014 10.1200/JCO.2008.19.9109 10.1016/0360-3016(95)00060-C 10.1002/(SICI)1097-0347(200005)22:3<275::AID-HED10>3.0.CO;2-N 10.1002/cncr.31741 10.1007/s12094-018-1988-z 10.1016/0360-3016(93)90493-F 10.2307/2531021 10.1016/0360-3016(92)90740-9 10.1016/j.oraloncology.2017.03.010 10.1200/JCO.20.03237 10.1002/hed.23314 10.1016/j.radonc.2013.10.010 10.1016/j.oraloncology.2015.10.020 10.12788/j.suponc.0005 10.1016/j.ijrobp.2017.03.007 10.6004/jnccn.2017.0121 10.1002/cncr.28201 |
ContentType | Journal Article |
Copyright | 2022 Elsevier Ltd Elsevier Ltd Copyright © 2022 Elsevier Ltd. All rights reserved. 2022. Elsevier Ltd |
Copyright_xml | – notice: 2022 Elsevier Ltd – notice: Elsevier Ltd – notice: Copyright © 2022 Elsevier Ltd. All rights reserved. – notice: 2022. Elsevier Ltd |
DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 0TZ 3V. 7RV 7TO 7X7 7XB 88E 8AO 8C1 8C2 8FI 8FJ 8FK ABUWG AFKRA BENPR CCPQU FYUFA GHDGH H94 K9. KB0 M0S M1P NAPCQ PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 |
DOI | 10.1016/S1470-2045(22)00058-4 |
DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Pharma and Biotech Premium PRO ProQuest Central (Corporate) Nursing & Allied Health Database Oncogenes and Growth Factors Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Pharma Collection Public Health Database Lancet Titles Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central ProQuest One Community College Health Research Premium Collection Health Research Premium Collection (Alumni) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Database (Alumni Edition) Health & Medical Collection (Alumni) Medical Database Nursing & Allied Health Premium ProQuest Central Premium ProQuest One Academic ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Pharma and Biotech Premium PRO Oncogenes and Growth Factors Abstracts ProQuest One Academic Middle East (New) Lancet Titles ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Pharma Collection ProQuest Central China ProQuest Central Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Health & Medical Research Collection AIDS and Cancer Research Abstracts ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Public Health ProQuest One Academic Eastern Edition ProQuest Nursing & Allied Health Source ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest Nursing & Allied Health Source (Alumni) ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic MEDLINE Pharma and Biotech Premium PRO |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1474-5488 |
EndPage | 490 |
ExternalDocumentID | 35240053 10_1016_S1470_2045_22_00058_4 S1470204522000584 1_s2_0_S1470204522000584 |
Genre | Clinical Trial, Phase III Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov't Journal Article |
GeographicLocations | China |
GeographicLocations_xml | – name: China |
GrantInformation | Sun Yat-sen University Clinical Research 5010 Program, the Natural Science Foundation of Guangdong Province, and the Overseas Expertise Introduction Project for Discipline Innovation. |
GroupedDBID | --- --K --M -RU .1- .55 .FO 0R~ 123 1B1 1P~ 1~5 29L 4.4 457 4CK 4G. 53G 5VS 6PF 7-5 71M 7RV 7X7 88E 8AO 8C1 8C2 8FI 8FJ AAEDT AAEDW AAIKJ AAKOC AALRI AAMRU AAQFI AAQQT AAQXK AATTM AAWTL AAXKI AAXUO AAYWO ABBQC ABMAC ABMZM ABUWG ABWVN ACGFS ACIEU ACPRK ACRLP ACRPL ACVFH ADBBV ADCNI ADMUD ADNMO AEIPS AEKER AENEX AEUPX AEVXI AFKRA AFPUW AFRHN AFTJW AFXIZ AGCQF AGHFR AGQPQ AHMBA AIGII AIIUN AITUG AJRQY AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ ANZVX APXCP ASPBG AVWKF AXJTR AZFZN BENPR BKEYQ BKOJK BNPGV BPHCQ BVXVI CCPQU CS3 DU5 EBS EFJIC EFKBS EJD EO8 EO9 EP2 EP3 EX3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN FYUFA G-Q GBLVA HMCUK HVGLF HZ~ IHE J1W KOM M1P M41 MO0 N9A NAPCQ O-L O9- OC~ OO- OZT P-8 P-9 P2P PCD PHGZM PHGZT PJZUB PPXIY PQQKQ PROAC PSQYO PUEGO R2- ROL RPZ SDG SEL SES SPCBC SSH SSZ T5K TLN UKHRP UV1 WOW X7M XBR Z5R 3V. AACTN AFCTW AFKWA AJOXV ALIPV AMFUW RIG SDF ABLVK ABYKQ AHPSJ AJBFU ZA5 AAYXX AGRNS CITATION CGR CUY CVF ECM EIF NPM 0TZ 7TO 7XB 8FK H94 K9. PKEHL PQEST PQUKI PRINS 7X8 |
ID | FETCH-LOGICAL-c502t-8ac2174334bc152ff221837e055233e4b49379360df17bd3fbdacd52eb3c5d823 |
IEDL.DBID | 7X7 |
ISSN | 1470-2045 1474-5488 |
IngestDate | Fri Jul 11 13:02:49 EDT 2025 Fri Jul 25 04:49:24 EDT 2025 Mon Jul 21 06:09:31 EDT 2025 Thu Apr 24 23:10:41 EDT 2025 Tue Jul 01 01:53:27 EDT 2025 Fri Feb 23 02:39:12 EST 2024 Tue Feb 25 20:02:55 EST 2025 Tue Aug 26 16:33:27 EDT 2025 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 4 |
Language | English |
License | Copyright © 2022 Elsevier Ltd. All rights reserved. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c502t-8ac2174334bc152ff221837e055233e4b49379360df17bd3fbdacd52eb3c5d823 |
Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 content type line 14 ObjectType-Feature-3 ObjectType-Evidence Based Healthcare-1 ObjectType-Article-1 ObjectType-Feature-2 content type line 23 ObjectType-Undefined-3 |
PMID | 35240053 |
PQID | 2644337003 |
PQPubID | 46089 |
PageCount | 12 |
ParticipantIDs | proquest_miscellaneous_2636141500 proquest_journals_2644337003 pubmed_primary_35240053 crossref_primary_10_1016_S1470_2045_22_00058_4 crossref_citationtrail_10_1016_S1470_2045_22_00058_4 elsevier_sciencedirect_doi_10_1016_S1470_2045_22_00058_4 elsevier_clinicalkeyesjournals_1_s2_0_S1470204522000584 elsevier_clinicalkey_doi_10_1016_S1470_2045_22_00058_4 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2022-04-01 |
PublicationDateYYYYMMDD | 2022-04-01 |
PublicationDate_xml | – month: 04 year: 2022 text: 2022-04-01 day: 01 |
PublicationDecade | 2020 |
PublicationPlace | England |
PublicationPlace_xml | – name: England – name: London |
PublicationTitle | The lancet oncology |
PublicationTitleAlternate | Lancet Oncol |
PublicationYear | 2022 |
Publisher | Elsevier Ltd Elsevier Limited |
Publisher_xml | – name: Elsevier Ltd – name: Elsevier Limited |
References | Lo, Wang, Ko (bib25) 2012; 19 Chen, Tang, Sun (bib10) 2014; 36 Lee, Poon, Foo (bib26) 1992; 23 Guo, Tang, Mao (bib23) 2019; 125 Li, Yuan, Zhang (bib28) 2013; 119 Lv, Cao, Xia (bib16) 2021; 22 Cox, Stetz, Pajak (bib14) 1995; 31 Grégoire, Ang, Budach (bib12) 2014; 110 Bray, Ferlay, Soerjomataram, Siegel, Torre, Jemal (bib1) 2018; 68 Fayers, Aaronson, Bjordal (bib21) 2001 Tang, Mao, Liu (bib5) 2009; 115 Lee, Foo, Law (bib3) 1997; 3 Licitra, Mesía, Keilholz (bib30) 2016; 52 Chen, Chan, Le, Blanchard, Sun, Ma (bib2) 2019; 394 Sham, Cheung, Choy, Chan, Leong (bib27) 1993; 26 Lai, Li, Chen (bib15) 2011; 80 Sommat, Ong, Hussain (bib6) 2017; 98 Tang, Tang, Li (bib8) 2017; 69 King, Ahuja, Leung (bib4) 2000; 22 Pong, Urner, Fowler (bib17) 2021; 11 Al-Mamgani, van Rooij, Tans, Verduijn, Sewnaik, Baatenburg de Jong (bib31) 2013; 106 Tang, Chen, Mao (bib24) 2017; 15 Lee, Harris, Garden (bib7) 2009; 27 Chen, Ismaila, Chua (bib13) 2021; 39 Schoenfeld (bib19) 1982; 39 Tang, Chen, Guo (bib18) 2018; 19 Fisher, Copas, Tierney, Parmar (bib20) 2011; 64 Xiao, Dou, Li (bib9) 2019; 21 Li, Sun, Chen (bib11) 2012; 31 de Veij Mestdagh, Walraven, Vogel (bib32) 2020; 147 Mehanna, Robinson, Hartley (bib22) 2019; 393 Murphy (bib29) 2013; 11 Grégoire (10.1016/S1470-2045(22)00058-4_bib12) 2014; 110 Tang (10.1016/S1470-2045(22)00058-4_bib18) 2018; 19 Fisher (10.1016/S1470-2045(22)00058-4_bib20) 2011; 64 Xiao (10.1016/S1470-2045(22)00058-4_bib9) 2019; 21 Sommat (10.1016/S1470-2045(22)00058-4_bib6) 2017; 98 Tang (10.1016/S1470-2045(22)00058-4_bib8) 2017; 69 Schoenfeld (10.1016/S1470-2045(22)00058-4_bib19) 1982; 39 Murphy (10.1016/S1470-2045(22)00058-4_bib29) 2013; 11 Lee (10.1016/S1470-2045(22)00058-4_bib7) 2009; 27 Chen (10.1016/S1470-2045(22)00058-4_bib13) 2021; 39 Lee (10.1016/S1470-2045(22)00058-4_bib26) 1992; 23 Guo (10.1016/S1470-2045(22)00058-4_bib23) 2019; 125 Lo (10.1016/S1470-2045(22)00058-4_bib25) 2012; 19 Tang (10.1016/S1470-2045(22)00058-4_bib24) 2017; 15 Al-Mamgani (10.1016/S1470-2045(22)00058-4_bib31) 2013; 106 Sham (10.1016/S1470-2045(22)00058-4_bib27) 1993; 26 King (10.1016/S1470-2045(22)00058-4_bib4) 2000; 22 Chen (10.1016/S1470-2045(22)00058-4_bib2) 2019; 394 Lai (10.1016/S1470-2045(22)00058-4_bib15) 2011; 80 Li (10.1016/S1470-2045(22)00058-4_bib28) 2013; 119 de Veij Mestdagh (10.1016/S1470-2045(22)00058-4_bib32) 2020; 147 Lv (10.1016/S1470-2045(22)00058-4_bib16) 2021; 22 Licitra (10.1016/S1470-2045(22)00058-4_bib30) 2016; 52 Lee (10.1016/S1470-2045(22)00058-4_bib3) 1997; 3 Chen (10.1016/S1470-2045(22)00058-4_bib10) 2014; 36 Tang (10.1016/S1470-2045(22)00058-4_bib5) 2009; 115 Li (10.1016/S1470-2045(22)00058-4_bib11) 2012; 31 Pong (10.1016/S1470-2045(22)00058-4_bib17) 2021; 11 Cox (10.1016/S1470-2045(22)00058-4_bib14) 1995; 31 Fayers (10.1016/S1470-2045(22)00058-4_bib21) 2001 Mehanna (10.1016/S1470-2045(22)00058-4_bib22) 2019; 393 Bray (10.1016/S1470-2045(22)00058-4_bib1) 2018; 68 35654058 - Lancet Oncol. 2022 Jun;23(6):e241 35654056 - Lancet Oncol. 2022 Jun;23(6):e239 35951036 - Strahlenther Onkol. 2022 Nov;198(11):1042-1044 36096750 - Chin Clin Oncol. 2022 Jan;11(5):35 35240054 - Lancet Oncol. 2022 Apr;23(4):441-443 35654057 - Lancet Oncol. 2022 Jun;23(6):e240 |
References_xml | – volume: 22 start-page: 275 year: 2000 end-page: 281 ident: bib4 article-title: Neck node metastases from nasopharyngeal carcinoma: MR imaging of patterns of disease publication-title: Head Neck – volume: 11 start-page: 149 year: 2013 end-page: 159 ident: bib29 article-title: To treat or not to treat: balancing therapeutic outcomes, toxicity and quality of life in patients with recurrent and/or metastatic head and neck cancer publication-title: J Support Oncol – volume: 147 start-page: 56 year: 2020 end-page: 63 ident: bib32 article-title: SPECT/CT-guided elective nodal irradiation for head and neck cancer is oncologically safe and less toxic: a potentially practice-changing approach publication-title: Radiother Oncol – volume: 64 start-page: 949 year: 2011 end-page: 967 ident: bib20 article-title: A critical review of methods for the assessment of patient-level interactions in individual participant data meta-analysis of randomized trials, and guidance for practitioners publication-title: J Clin Epidemiol – volume: 23 start-page: 261 year: 1992 end-page: 270 ident: bib26 article-title: Retrospective analysis of 5037 patients with nasopharyngeal carcinoma treated during 1976–1985: overall survival and patterns of failure publication-title: Int J Radiat Oncol Biol Phys – volume: 39 start-page: 840 year: 2021 end-page: 859 ident: bib13 article-title: Chemotherapy in combination with radiotherapy for definitive-intent treatment of stage II-IVA nasopharyngeal carcinoma: CSCO and ASCO Guideline publication-title: J Clin Oncol – volume: 394 start-page: 64 year: 2019 end-page: 80 ident: bib2 article-title: Nasopharyngeal carcinoma publication-title: Lancet – volume: 69 start-page: 68 year: 2017 end-page: 73 ident: bib8 article-title: The feasibility of contralateral lower neck sparing intensity modulation radiated therapy for nasopharyngeal carcinoma patients with unilateral cervical lymph node involvement publication-title: Oral Oncol – volume: 15 start-page: 913 year: 2017 end-page: 919 ident: bib24 article-title: Validation of the 8th Edition of the UICC/AJCC Staging System for nasopharyngeal carcinoma from endemic areas in the intensity-modulated radiotherapy era publication-title: J Natl Compr Canc Netw – volume: 27 start-page: 3684 year: 2009 end-page: 3690 ident: bib7 article-title: Intensity-modulated radiation therapy with or without chemotherapy for nasopharyngeal carcinoma: Radiation Therapy Oncology Group phase II trial 0225 publication-title: J Clin Oncol – volume: 26 start-page: 787 year: 1993 end-page: 792 ident: bib27 article-title: Computed tomography evaluation of neck node metastases from nasopharyngeal carcinoma publication-title: Int J Radiat Oncol Biol Phys – volume: 31 start-page: 1341 year: 1995 end-page: 1346 ident: bib14 article-title: Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC) publication-title: Int J Radiat Oncol Biol Phys – volume: 39 start-page: 499 year: 1982 end-page: 503 ident: bib19 article-title: Sample-size formula for the proportional-hazards regression model publication-title: Biometrics – volume: 115 start-page: 680 year: 2009 end-page: 688 ident: bib5 article-title: The volume to be irradiated during selective neck irradiation in nasopharyngeal carcinoma: analysis of the spread patterns in lymph nodes by magnetic resonance imaging publication-title: Cancer – volume: 98 start-page: 574 year: 2017 end-page: 580 ident: bib6 article-title: Thyroid V40 predicts primary hypothyroidism after intensity modulated radiation therapy for nasopharyngeal carcinoma publication-title: Int J Radiat Oncol Biol Phys – volume: 80 start-page: 661 year: 2011 end-page: 668 ident: bib15 article-title: How does intensity-modulated radiotherapy versus conventional two-dimensional radiotherapy influence the treatment results in nasopharyngeal carcinoma patients? publication-title: Int J Radiat Oncol Biol Phys – volume: 22 start-page: 716 year: 2021 end-page: 726 ident: bib16 article-title: Induction chemotherapy with lobaplatin and fluorouracil versus cisplatin and fluorouracil followed by chemoradiotherapy in patients with stage III–IVB nasopharyngeal carcinoma: an open-label, non-inferiority, randomised, controlled, phase 3 trial publication-title: Lancet Oncol – volume: 52 start-page: 18 year: 2016 end-page: 23 ident: bib30 article-title: Individualised quality of life as a measure to guide treatment choices in squamous cell carcinoma of the head and neck publication-title: Oral Oncol – year: 2001 ident: bib21 article-title: EORTC QLQ-C30 scoring manual – volume: 36 start-page: 468 year: 2014 end-page: 473 ident: bib10 article-title: Treatment outcomes and feasibility of partial neck irradiation for patients with nasopharyngeal carcinoma with only retropharyngeal lymph node metastasis after intensity-modulated radiotherapy publication-title: Head Neck – volume: 19 start-page: 1001 year: 2012 end-page: 1008 ident: bib25 article-title: Salvage treatment for isolated regional failure of nasopharyngeal carcinoma after primary radiotherapy publication-title: Ann Surg Oncol – volume: 11 year: 2021 ident: bib17 article-title: Testing for non-inferior mortality: a systematic review of non-inferiority margin sizes and trial characteristics publication-title: BMJ Open – volume: 31 start-page: 579 year: 2012 end-page: 587 ident: bib11 article-title: Locoregional extension patterns of nasopharyngeal carcinoma and suggestions for clinical target volume delineation publication-title: Chin J Cancer – volume: 106 start-page: 359 year: 2013 end-page: 363 ident: bib31 article-title: A prospective evaluation of patient-reported quality-of-life after (chemo)radiation for oropharyngeal cancer: which patients are at risk of significant quality-of-life deterioration? publication-title: Radiother Oncol – volume: 110 start-page: 172 year: 2014 end-page: 181 ident: bib12 article-title: Delineation of the neck node levels for head and neck tumors: a 2013 update. DAHANCA, EORTC, HKNPCSG, NCIC CTG, NCRI, RTOG, TROG consensus guidelines publication-title: Radiother Oncol – volume: 21 start-page: 781 year: 2019 end-page: 789 ident: bib9 article-title: Omitting the lower neck and sparing the glottic larynx in node-negative nasopharyngeal carcinoma was safe and feasible, and improved patient-reported voice outcomes publication-title: Clin Transl Oncol – volume: 125 start-page: 79 year: 2019 end-page: 89 ident: bib23 article-title: Proposed modifications and incorporation of plasma Epstein-Barr virus DNA improve the TNM staging system for Epstein-Barr virus-related nasopharyngeal carcinoma publication-title: Cancer – volume: 68 start-page: 394 year: 2018 end-page: 424 ident: bib1 article-title: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries publication-title: CA Cancer J Clin – volume: 119 start-page: 3170 year: 2013 end-page: 3176 ident: bib28 article-title: A randomized clinical trial comparing prophylactic upper versus whole-neck irradiation in the treatment of patients with node-negative nasopharyngeal carcinoma publication-title: Cancer – volume: 19 start-page: 461 year: 2018 end-page: 473 ident: bib18 article-title: Concurrent chemoradiotherapy with nedaplatin versus cisplatin in stage II-IVB nasopharyngeal carcinoma: an open-label, non-inferiority, randomised phase 3 trial publication-title: Lancet Oncol – volume: 393 start-page: 51 year: 2019 end-page: 60 ident: bib22 article-title: Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial publication-title: Lancet – volume: 3 start-page: 355 year: 1997 end-page: 361 ident: bib3 article-title: Nasopharyngeal carcinoma: presenting symptoms and duration before diagnosis publication-title: Hong Kong Med J – volume: 19 start-page: 461 year: 2018 ident: 10.1016/S1470-2045(22)00058-4_bib18 article-title: Concurrent chemoradiotherapy with nedaplatin versus cisplatin in stage II-IVB nasopharyngeal carcinoma: an open-label, non-inferiority, randomised phase 3 trial publication-title: Lancet Oncol doi: 10.1016/S1470-2045(18)30104-9 – volume: 31 start-page: 579 year: 2012 ident: 10.1016/S1470-2045(22)00058-4_bib11 article-title: Locoregional extension patterns of nasopharyngeal carcinoma and suggestions for clinical target volume delineation publication-title: Chin J Cancer doi: 10.5732/cjc.012.10095 – volume: 64 start-page: 949 year: 2011 ident: 10.1016/S1470-2045(22)00058-4_bib20 article-title: A critical review of methods for the assessment of patient-level interactions in individual participant data meta-analysis of randomized trials, and guidance for practitioners publication-title: J Clin Epidemiol doi: 10.1016/j.jclinepi.2010.11.016 – year: 2001 ident: 10.1016/S1470-2045(22)00058-4_bib21 – volume: 393 start-page: 51 year: 2019 ident: 10.1016/S1470-2045(22)00058-4_bib22 article-title: Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial publication-title: Lancet doi: 10.1016/S0140-6736(18)32752-1 – volume: 394 start-page: 64 year: 2019 ident: 10.1016/S1470-2045(22)00058-4_bib2 article-title: Nasopharyngeal carcinoma publication-title: Lancet doi: 10.1016/S0140-6736(19)30956-0 – volume: 22 start-page: 716 year: 2021 ident: 10.1016/S1470-2045(22)00058-4_bib16 article-title: Induction chemotherapy with lobaplatin and fluorouracil versus cisplatin and fluorouracil followed by chemoradiotherapy in patients with stage III–IVB nasopharyngeal carcinoma: an open-label, non-inferiority, randomised, controlled, phase 3 trial publication-title: Lancet Oncol doi: 10.1016/S1470-2045(21)00075-9 – volume: 19 start-page: 1001 year: 2012 ident: 10.1016/S1470-2045(22)00058-4_bib25 article-title: Salvage treatment for isolated regional failure of nasopharyngeal carcinoma after primary radiotherapy publication-title: Ann Surg Oncol doi: 10.1245/s10434-011-2018-3 – volume: 68 start-page: 394 year: 2018 ident: 10.1016/S1470-2045(22)00058-4_bib1 article-title: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries publication-title: CA Cancer J Clin doi: 10.3322/caac.21492 – volume: 80 start-page: 661 year: 2011 ident: 10.1016/S1470-2045(22)00058-4_bib15 article-title: How does intensity-modulated radiotherapy versus conventional two-dimensional radiotherapy influence the treatment results in nasopharyngeal carcinoma patients? publication-title: Int J Radiat Oncol Biol Phys doi: 10.1016/j.ijrobp.2010.03.024 – volume: 115 start-page: 680 year: 2009 ident: 10.1016/S1470-2045(22)00058-4_bib5 article-title: The volume to be irradiated during selective neck irradiation in nasopharyngeal carcinoma: analysis of the spread patterns in lymph nodes by magnetic resonance imaging publication-title: Cancer doi: 10.1002/cncr.24049 – volume: 11 year: 2021 ident: 10.1016/S1470-2045(22)00058-4_bib17 article-title: Testing for non-inferior mortality: a systematic review of non-inferiority margin sizes and trial characteristics publication-title: BMJ Open doi: 10.1136/bmjopen-2020-044480 – volume: 147 start-page: 56 year: 2020 ident: 10.1016/S1470-2045(22)00058-4_bib32 article-title: SPECT/CT-guided elective nodal irradiation for head and neck cancer is oncologically safe and less toxic: a potentially practice-changing approach publication-title: Radiother Oncol doi: 10.1016/j.radonc.2020.03.012 – volume: 3 start-page: 355 year: 1997 ident: 10.1016/S1470-2045(22)00058-4_bib3 article-title: Nasopharyngeal carcinoma: presenting symptoms and duration before diagnosis publication-title: Hong Kong Med J – volume: 106 start-page: 359 year: 2013 ident: 10.1016/S1470-2045(22)00058-4_bib31 article-title: A prospective evaluation of patient-reported quality-of-life after (chemo)radiation for oropharyngeal cancer: which patients are at risk of significant quality-of-life deterioration? publication-title: Radiother Oncol doi: 10.1016/j.radonc.2012.12.014 – volume: 27 start-page: 3684 year: 2009 ident: 10.1016/S1470-2045(22)00058-4_bib7 article-title: Intensity-modulated radiation therapy with or without chemotherapy for nasopharyngeal carcinoma: Radiation Therapy Oncology Group phase II trial 0225 publication-title: J Clin Oncol doi: 10.1200/JCO.2008.19.9109 – volume: 31 start-page: 1341 year: 1995 ident: 10.1016/S1470-2045(22)00058-4_bib14 article-title: Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC) publication-title: Int J Radiat Oncol Biol Phys doi: 10.1016/0360-3016(95)00060-C – volume: 22 start-page: 275 year: 2000 ident: 10.1016/S1470-2045(22)00058-4_bib4 article-title: Neck node metastases from nasopharyngeal carcinoma: MR imaging of patterns of disease publication-title: Head Neck doi: 10.1002/(SICI)1097-0347(200005)22:3<275::AID-HED10>3.0.CO;2-N – volume: 125 start-page: 79 year: 2019 ident: 10.1016/S1470-2045(22)00058-4_bib23 article-title: Proposed modifications and incorporation of plasma Epstein-Barr virus DNA improve the TNM staging system for Epstein-Barr virus-related nasopharyngeal carcinoma publication-title: Cancer doi: 10.1002/cncr.31741 – volume: 21 start-page: 781 year: 2019 ident: 10.1016/S1470-2045(22)00058-4_bib9 article-title: Omitting the lower neck and sparing the glottic larynx in node-negative nasopharyngeal carcinoma was safe and feasible, and improved patient-reported voice outcomes publication-title: Clin Transl Oncol doi: 10.1007/s12094-018-1988-z – volume: 26 start-page: 787 year: 1993 ident: 10.1016/S1470-2045(22)00058-4_bib27 article-title: Computed tomography evaluation of neck node metastases from nasopharyngeal carcinoma publication-title: Int J Radiat Oncol Biol Phys doi: 10.1016/0360-3016(93)90493-F – volume: 39 start-page: 499 year: 1982 ident: 10.1016/S1470-2045(22)00058-4_bib19 article-title: Sample-size formula for the proportional-hazards regression model publication-title: Biometrics doi: 10.2307/2531021 – volume: 23 start-page: 261 year: 1992 ident: 10.1016/S1470-2045(22)00058-4_bib26 article-title: Retrospective analysis of 5037 patients with nasopharyngeal carcinoma treated during 1976–1985: overall survival and patterns of failure publication-title: Int J Radiat Oncol Biol Phys doi: 10.1016/0360-3016(92)90740-9 – volume: 69 start-page: 68 year: 2017 ident: 10.1016/S1470-2045(22)00058-4_bib8 article-title: The feasibility of contralateral lower neck sparing intensity modulation radiated therapy for nasopharyngeal carcinoma patients with unilateral cervical lymph node involvement publication-title: Oral Oncol doi: 10.1016/j.oraloncology.2017.03.010 – volume: 39 start-page: 840 year: 2021 ident: 10.1016/S1470-2045(22)00058-4_bib13 article-title: Chemotherapy in combination with radiotherapy for definitive-intent treatment of stage II-IVA nasopharyngeal carcinoma: CSCO and ASCO Guideline publication-title: J Clin Oncol doi: 10.1200/JCO.20.03237 – volume: 36 start-page: 468 year: 2014 ident: 10.1016/S1470-2045(22)00058-4_bib10 article-title: Treatment outcomes and feasibility of partial neck irradiation for patients with nasopharyngeal carcinoma with only retropharyngeal lymph node metastasis after intensity-modulated radiotherapy publication-title: Head Neck doi: 10.1002/hed.23314 – volume: 110 start-page: 172 year: 2014 ident: 10.1016/S1470-2045(22)00058-4_bib12 article-title: Delineation of the neck node levels for head and neck tumors: a 2013 update. DAHANCA, EORTC, HKNPCSG, NCIC CTG, NCRI, RTOG, TROG consensus guidelines publication-title: Radiother Oncol doi: 10.1016/j.radonc.2013.10.010 – volume: 52 start-page: 18 year: 2016 ident: 10.1016/S1470-2045(22)00058-4_bib30 article-title: Individualised quality of life as a measure to guide treatment choices in squamous cell carcinoma of the head and neck publication-title: Oral Oncol doi: 10.1016/j.oraloncology.2015.10.020 – volume: 11 start-page: 149 year: 2013 ident: 10.1016/S1470-2045(22)00058-4_bib29 article-title: To treat or not to treat: balancing therapeutic outcomes, toxicity and quality of life in patients with recurrent and/or metastatic head and neck cancer publication-title: J Support Oncol doi: 10.12788/j.suponc.0005 – volume: 98 start-page: 574 year: 2017 ident: 10.1016/S1470-2045(22)00058-4_bib6 article-title: Thyroid V40 predicts primary hypothyroidism after intensity modulated radiation therapy for nasopharyngeal carcinoma publication-title: Int J Radiat Oncol Biol Phys doi: 10.1016/j.ijrobp.2017.03.007 – volume: 15 start-page: 913 year: 2017 ident: 10.1016/S1470-2045(22)00058-4_bib24 article-title: Validation of the 8th Edition of the UICC/AJCC Staging System for nasopharyngeal carcinoma from endemic areas in the intensity-modulated radiotherapy era publication-title: J Natl Compr Canc Netw doi: 10.6004/jnccn.2017.0121 – volume: 119 start-page: 3170 year: 2013 ident: 10.1016/S1470-2045(22)00058-4_bib28 article-title: A randomized clinical trial comparing prophylactic upper versus whole-neck irradiation in the treatment of patients with node-negative nasopharyngeal carcinoma publication-title: Cancer doi: 10.1002/cncr.28201 – reference: 35654057 - Lancet Oncol. 2022 Jun;23(6):e240 – reference: 35951036 - Strahlenther Onkol. 2022 Nov;198(11):1042-1044 – reference: 35240054 - Lancet Oncol. 2022 Apr;23(4):441-443 – reference: 36096750 - Chin Clin Oncol. 2022 Jan;11(5):35 – reference: 35654058 - Lancet Oncol. 2022 Jun;23(6):e241 – reference: 35654056 - Lancet Oncol. 2022 Jun;23(6):e239 |
SSID | ssj0017105 |
Score | 2.6059356 |
Snippet | The aim of this trial was to address whether elective ipsilateral upper-neck irradiation (UNI) sparing the uninvolved lower neck provides similar regional... SummaryBackgroundThe aim of this trial was to address whether elective ipsilateral upper-neck irradiation (UNI) sparing the uninvolved lower neck provides... Summary Background The aim of this trial was to address whether elective ipsilateral upper-neck irradiation (UNI) sparing the uninvolved lower neck provides... |
SourceID | proquest pubmed crossref elsevier |
SourceType | Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 479 |
SubjectTerms | Adolescent Adult Aged Antineoplastic Combined Chemotherapy Protocols - therapeutic use Cancer Chemoradiotherapy Chemoradiotherapy - adverse effects Chemoradiotherapy - methods Chemotherapy Cisplatin Clinical trials Dermatomyositis Dysphagia Epstein-Barr virus Hematology Hematology, Oncology, and Palliative Medicine Humans Hypothyroidism Intravenous administration Lymph nodes Lymphatic system Metastases Metastasis Middle Aged Nasopharyngeal carcinoma Nasopharyngeal Carcinoma - drug therapy Nasopharyngeal Carcinoma - radiotherapy Nasopharyngeal Neoplasms - pathology Neck Neoplasm Recurrence, Local - pathology Neoplasm Staging Patients Quality of life Radiation Radiation therapy Spinal cord Survival Throat cancer Toxicity Translation Tumors Young Adult |
Title | Elective upper-neck versus whole-neck irradiation of the uninvolved neck in patients with nasopharyngeal carcinoma: an open-label, non-inferiority, multicentre, randomised phase 3 trial |
URI | https://www.clinicalkey.com/#!/content/1-s2.0-S1470204522000584 https://www.clinicalkey.es/playcontent/1-s2.0-S1470204522000584 https://dx.doi.org/10.1016/S1470-2045(22)00058-4 https://www.ncbi.nlm.nih.gov/pubmed/35240053 https://www.proquest.com/docview/2644337003 https://www.proquest.com/docview/2636141500 |
Volume | 23 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1Nb9QwELWglRAXxDdbSmUkDiCtaWI7mywXBNVWFRIVAirtzXJsB1YsTprsgvhp_DtmHCe9UMolh8Rjr3YmM2_i8TxCns2MkZBJZExYkTNZyJTNs1wwoXXFK6R2sKHb5-ns5Ey-W2bL-MGti2WVg08MjtrWBr-RH2LgFiIHI3zdnDNkjcLd1UihcZ3sYusytOp8OSZcad6XMKYyTxi2Xb84wXP4abz5nPMXiFwKJi-LTZdhzxCDjm-TWxE80je9tu-Qa87fJTfex-3xe-T3Yt37L7ptGtcy78w3inUX247-RCLc_s6qbbEjAaqE1hUFCEi3fuXBUf1wlvZDPI0dV0FytflKvUa-A93-8l8AWlKDFES-_q5fUQ2TNM4zMCe3nlJfe4YVXu2qRl68KQ0li6EG1E0pREZbg2nBOjBb56iggTfkPjk7Xnw-OmGRm4GZLOEbVmgTkhkhSwMQoKo4Yq3cJRlktsLJUgLumYtZYqs0L62oSquNzTjk7iazBRcPyA78IPeIUF2AI5i7pHKllGU2L0oHaWsJybMuQONiQuSgFWVi43Lkz1irsUINlalQmYpzFZSp5IS8HMWavnPHVQKzQeVqOJYKjlRBbLlKMP-boOuiO-hUqjoY3Uvz0MQ-iIJkMUpGxNMjmf9ZdH-wSjWuc_GSTMjT8TFoFXeBtHf1FscIgGSQByQT8rC35vH_ATQu0S3v_Xvyx-Qmx1MgoYBpn-xs2q17AthsUx6EFxCuxVF6QHbfLk4_fPwD3880Ew |
linkProvider | ProQuest |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwELaqIgEXxJstBYwEEkhrmtjOJouEECqttvRxoZV6M47jwKqLE5INVf8Ud_4dM86jF0q59Jr12NHOeOabeDwfIS8mxkjIJCImMhEzmciQTaNYMKF1znOkdsh8t8-DyexIfjqOjlfIr_4uDJZV9j7RO-qsMPiNfAMDtxAxGOH78gdD1ig8Xe0pNFqz2LVnp5Cy1e92PoJ-X3K-vXW4OWMdqwAzUcCXLNHGw3AhUwPBK885ooTYBhHkZMLKVELEnopJkOVhnGYiTzNtsohD1mmiLMFGB-Dyr-HL4I5KNoeSkjBuSyZDGQcM27yf3xja-Dw8fMX5a0RKCZMXxcKLsK6Pedu3ya0OrNIPrXXdISvW3SXX97vj-Hvk99ai9Ze0KUtbMWfNCcU6j6amp0i82z6ZVxV2QEAToEVOAXLSxs0dOMafNqPtEEe7Dq8gOV9-o04jv4KuztxXgLLUIOWRK77rt1TDJKV1DMzXLsbUFY5hRVk1L5CHb0x9iaSvObVjCpE4K8CUYR2YrbZUUM9Tcp8cXYnWHpBVeCH7iFCdgOOZ2iC3qZRpNE1SC2lyCsm6TkCpYkRkrxVlukbpyNexUENFHCpToTIV58orU8kReTOIlW2nkMsEJr3KVX8NFhy3glh2mWD8N0Fbd-6nVqGqYXQrzX3TfC8Kkskg2SGsFjn9z6LrvVWqYZ3zTTkiz4efQat46qSdLRocIwACQt4RjMjD1pqH_wfQv8QwsPbvyZ-RG7PD_T21t3Ow-5jc5HgDxRdPrZPVZdXYJ4ALl-lTvxkp-XLVu_8PGh1tlQ |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3db9MwELemIU28oPFdGGAkkECqWWI7TYqEENpWbQwmJJi0N89xHFZRnJA0TPvT4K_jzvnYC2O87DX12W3vfPe7-Hw_Qp5NjJGQSURMZCJmMpEhm0axYELrnOdI7ZD5bp8Hk91D-f4oOlohv_u7MFhW2ftE76izwuA78k0M3ELE-N4t78oiPm3P3pY_GDJI4UlrT6fRmsi-PTuF9K1-s7cNun7O-Wzny9Yu6xgGmIkCvmSJNh6SC5kaCGR5zhExxDaIID8TVqYSovdUTIIsD-M0E3maaZNFHDJQE2UJNj0A938tFvCb8Jb61lBeEsZt-WQo44Bhy_fz20Obn4eHLzh_iagpYfKiuHgR7vXxb7ZObnTAlb5rLe0mWbHuFln72B3N3ya_dhat76RNWdqKOWu-Uaz5aGp6iiS87ZN5VWE3BDQHWuQU4Cdt3NyBk_xpM9oOcbTr9gqS8-UJdRq5FnR15r4CrKUG6Y9c8V2_phomKa1jYMp2MaaucAyry6p5gZx8Y-rLJX39qR1TiMpZAWYN68BstaWCes6SO-TwSrR2l6zCF7L3CdUJOKGpDXKbSplG0yS1kDKnkLjrBKxNjIjstaJM1zQduTsWaqiOQ2UqVKbiXHllKjkirwaxsu0acpnApFe56q_EghNXENcuE4z_JmjrzhXVKlQ1jG6luW-g70VBMhkkO7TVoqj_WXSjt0o1rHO-QUfk6fAxaBVPoLSzRYNjBMBByEGCEbnXWvPw_0AmIDEkPPj35E_IGux79WHvYP8huc7xMoqvo9ogq8uqsY8AIi7Tx34vUnJ81Zv_D5EMccs |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Elective+upper-neck+versus+whole-neck+irradiation+of+the+uninvolved+neck+in+patients+with+nasopharyngeal+carcinoma%3A+an+open-label%2C+non-inferiority%2C+multicentre%2C+randomised+phase+3+trial&rft.jtitle=The+lancet+oncology&rft.au=Tang%2C+Ling-Long&rft.au=Huang%2C+Cheng-Long&rft.au=Zhang%2C+Ning&rft.au=Jiang%2C+Wei&rft.date=2022-04-01&rft.pub=Elsevier+Ltd&rft.issn=1470-2045&rft.eissn=1474-5488&rft.volume=23&rft.issue=4&rft.spage=479&rft.epage=490&rft_id=info:doi/10.1016%2FS1470-2045%2822%2900058-4&rft.externalDocID=S1470204522000584 |
thumbnail_m | http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F14702045%2FS1470204522X00041%2Fcov150h.gif |